2021 Annual report clarifications

Current report

according to ASF Regulation no. 5/2018

Important events to report:

Dear investors,

          The Board of Administrators of Farmaceutica REMEDIA S.A. informs the shareholders about the erroneous mention of IAS 18 - Revenue, instead of IFRS 15 - Revenue from Contracts with Customers, in the Explanatory notes to the Consolidated and Unconsolidated Financial Statements for 2021:

1. The actual method of revenue recognition during 2021 was in accordance with IFRS 15 Revenue from Contracts with Customers, the basic principle of which is that an entity shall recognize revenue to describe the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

2. Due to an error in the Explanatory Notes, the standard applicable to revenue recognition (Note 3 Significant accounting policies) has not been updated, but the basic principles of the current standard (IFRS 15) have been followed.

3. In the financial auditor's report reference is made to the application of IAS 18 due to the omission of the update, but the basic principles of the standard in force (IFRS 15) have been respected.

4. According to the note issued by the financial auditor INTERAUDIT SRL (attached to this current report), a further analysis of the application of the revenue recognition principles under IFRS 15 has been performed and no differences in interpretation have been found that would have an impact on the consolidated and unconsolidated financial statements for 2021.

Additional information can be obtained by phone +40 254 223 260, contact persons: Elena CODREAN / Florin CADIA, or at the e-mail address investor@remedia.ro.

                                                          President of the Board of Administrators

                                                         „TARUS” – Valentin Norbert TARUS e.U.